Condorelli, Margherita http://orcid.org/0000-0002-1104-8208
Sens, Maëlle
Goldrat, Oranite http://orcid.org/0000-0002-7794-3133
Delbaere, Anne http://orcid.org/0000-0001-7236-0687
Racapé, Judith http://orcid.org/0000-0002-1266-0191
Lambertini, Matteo http://orcid.org/0000-0003-1797-5296
Demeestere, Isabelle http://orcid.org/0000-0002-3192-6565
Funding for this research was provided by:
Fonds De La Recherche Scientifique - FNRS (Télévie 7.6508.20)
Fonds Erasme
Associazione Italiana per la Ricerca sul Cancro (MFAG 2020 ID 24698)
Italian Ministry of Health
Article History
Received: 25 August 2021
Accepted: 7 December 2021
First Online: 18 January 2022
Declarations
:
: Matteo Lambertini acted as a consultant for Roche, Lilly, AstraZeneca, and Novartis and has received honoraria from Sandoz, Roche, Lilly, Pfizer, Novartis, and Takeda, outside the submitted work. Anne Delbaere received grants from Ferring Pharmaceuticals and consultancy or lecture fees from Merck, Gedeon-Richter Ferring Pharmaceuticals, and OVVI Diagnostics, outside the submitted work. Isabelle Demeestere received research grants from Ferring and Roche, consultancy or lecture fees from Roche, Novartis and support for attending meetings from Ferring and Theramex, outside the submitted work. The remaining authors have no conflicts of interest to declare.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the ethics committee of CUB-Hôpital Erasme (P2020.328).
: The need for obtaining informed consent was waived by the Hôpital Erasme ethical committee, given that this study was retrospective and non-interventional. Patients have the right to refuse to participate in any clinical trial by informing the hospital which keeps a record of their choice. We hereby confirm that we took into account patient preference and consequently excluded all patients that refused their participation in clinical trials.